Targeting CD19 in Diffuse Large B-Cell Lymphoma

EP. 1: Current Treatment Approach to Relapsed/Refractory DLBCL

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 2: CD19-Targeted CAR T-Cell Therapy in Managing DLBCL

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 3: CD19-Targeted MAbs in Relapsed/Refractory DLBCL

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 4: Transplant Ineligibility: Anti-CD19 Combination Therapy

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 5: L-MIND Combination Therapy Dosing Schedule

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 6: Re-MIND Versus L-MIND Regimen

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 7: CD19 and CD20 Antibodies in Development

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 8: The Future of DLBCL Management

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 9: Newly Diagnosed Relapsed/Refractory DLBCL

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 10: CAR T: CD19-Targeted Therapy in R/R DLBCL

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 11: Treatment of R/R DLBCL: CD19-Targeted Monoclonal Antibodies

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 12: L-MIND Study: R/R DLBCL

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021

EP. 13: Future Directions for R/R DLBCL

ByTargeted Oncology

Published: May 7th 2020 | Updated: April 27th 2021